Abstract
A better understanding of predisposition to transition to high-dose, long-term opioid therapy after initial opioid receipt could facilitate efforts to prevent opioid use disorder (OUD). We extracted data on 69,268 patients in the Veterans Aging Cohort Study who received any opioid prescription between 1998 and 2015. Using latent growth mixture modelling, we identified four distinguishable dose trajectories: low (53%), moderate (29%), escalating (13%), and rapidly escalating (5%). Compared to low dose trajectory, those in the rapidly escalating dose trajectory were proportionately more European-American (59% rapidly escalating vs. 38% low); had a higher prevalence of HIV (31% vs. 29%) and hepatitis C (18% vs. 12%); and during follow-up, had a higher incidence of OUD diagnoses (13% vs. 3%); were hospitalised more often [18.1/100 person-years (PYs) vs. 12.5/100 PY]; and had higher all-cause mortality (4.7/100 PY vs. 1.8/100 PY, all p < 0.0001). These measures can potentially be used in future prevention research, including genetic discovery.
Original language | English |
---|---|
Pages (from-to) | 3340-3349 |
Number of pages | 10 |
Journal | AIDS and Behavior |
Volume | 23 |
Issue number | 12 |
DOIs | |
State | Published - Dec 1 2019 |
Bibliographical note
Publisher Copyright:© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
Funding
This work was supported by US National Institutes of Health, including Grants from National Institute on Alcohol Abuse and Alcoholism (U24-AA020794, U01-AA020790, U10-AA013566-completed to ACJ) and National Institute on Drug Abuse (NIDA R01-DA040471, R01-DA12690). Additional support was provided by the US Department of Veterans Affairs (i01-BX003341), Yale School of Medicine Drug Use, Addiction, and HIV Research Scholars Program (DAHRS K12-DA033312), and Agency for Healthcare Research and Quality (AHRQ U19-HS021112 and R18-HS023258). The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The views presented in this paper are the authors’ and not necessarily those of the Department of Veterans Affairs or the United States Government.
Funders | Funder number |
---|---|
National Institutes of Health (NIH) | |
National Institute on Drug Abuse | R01DA040471 |
National Institute on Drug Abuse | |
National Institute on Alcohol Abuse and Alcoholism | U24-AA020794, U01-AA020790 |
National Institute on Alcohol Abuse and Alcoholism | |
Agency for Healthcare Research and Quality | R18-HS023258, U19-HS021112 |
Agency for Healthcare Research and Quality | |
U.S. Department of Veterans Affairs | |
Yale University School of Medicine | DAHRS K12-DA033312 |
Yale University School of Medicine | |
National Institute of Development Administration | R01-DA12690, R01-DA040471 |
National Institute of Development Administration |
Keywords
- Electronic health records
- Opioids
- Pharmacoepidemiology
- Pharmacy fill data
- Phenotype
ASJC Scopus subject areas
- Social Psychology
- Public Health, Environmental and Occupational Health
- Infectious Diseases